Several attributable factors to the growth of the global genetic engineering market include various emerging technologies and innovations in the healthcare and medicine sector, proliferated the use of genetic engineering in various countries and upscaling noted in the stem-cell division.
Genetic engineering refers to the manipulation of genes in an organism of species to enhance various abilities. This technology is used by biotechnology companies, pharmaceutical companies, and clinical research organizations. In medicine, gene therapy is prominently used for the treatment of cancer and various infectious diseases and disorders. The global genetic engineering market is anticipated to expand at 14.5% CAGR during the forecast period of 2018-2027.
Market segmentation
The global genetic engineering market report by Market Research Future includes a detailed analysis based on devices, product, application, end users, technique, and region. Different devices studied in the global genetic engineering market include biochemicals and genetic markers. Within biochemicals, different products such as restriction enzymes and RNAase are included in the report. Different restriction enzymes analyzed in the report areDNAase, metazoans, and micrococcal nuclease. RNAase is further divided into metazoans, RNase A, RNase H, and RNase III.
Within genetic markers, different products studied include RFLP (Restriction Fragment Length Polymorphism), AFLP (Amplified Fragment Length Polymorphism), and SSLP (Simple sequence length polymorphism).
Detailed regional analysis
Global genetic engineering market has been studied for various regions like the Americas, Europe, Asia Pacific, and The Middle East and Africa. Among these regions, the Americas genetic engineering market over the forecast period. Such market dominance can be attributed to the increasing genetic engineering applications in the form of gene therapy, neurological disorders such as Alzheimer's and dementia, and prevalence of cancer. Apart from this, increasing awareness towards the use of stem cells is also fuelling sizable growth interracial genetic engineering market.
Genetic engineering market in Europe is anticipated to upscale due to extensive research and development activities noted in the fields of biotechnology and genetic engineering. The European market is expected to witness consistent growth and trail behind the American market. Additionally, with a rise in demand for genetically modified organisms, Europe is expected to be a future growth pocket for genetic engineering market.
According to the new market research report “Regenerative Medicine Market by Type [Cell-Based Immunotherapy & Cell Therapy (Allogeneic & Autologous Products), Tissue Engineering, Gene Therapy], Applications (Wounds & Dermal, Musculoskeletal, Oncology), Region — Global Forecast to 2024”, published by MarketsandMarkets™, the Regenerative Medicine Market is expected to reach USD 38.7 billion by 2024 from USD 13.3 billion in 2019, at a CAGR of 23.8%.Growth in this market is largely driven by the introduction of Cures Act for regenerative medicine by FDA, increased funding for regenerative medicine research, development of CAR-T cell therapies and increasing demand for regenerative medicine for the treatment of cancer, orthopedic disorders, and chronic wounds among others.
Cell-based immunotherapy & cell therapy products segment dominated the Regenerative Medicine Market in 2019.On the basis of type, the Regenerative Medicine Market is classified into cell-based immunotherapy & cell therapy products, gene therapy products, and tissue-engineered products.
The cell-based immunotherapy & cell therapy products segment accounted for the largest market share in 2019 owing to increasing demand for cell-based immunotherapies, the establishment of cures act by FDA to streamline the regenerative medicine approval are the major factors driving the growth of this market segment.Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=65442579Browse and in-depth TOC on “Regenerative Medicine Market”76 — Tables29 — Figures107 — PagesMusculoskeletal disorders applications segment likely to dominate the market in 2019.On the basis of application, the Regenerative Medicine Market is categorized into musculoskeletal disorders, wound care, oncology, ocular disorders, diabetes, and other applications.
In 2019, the musculoskeletal disorders segment accounted for the largest market share.
The large share of this segment can mainly be attributed to the rising incidence rate of orthopedic diseases with a rising geriatric population.North America anticipated accounting for the largest share of the Regenerative Medicine Market in 2019.The Regenerative Medicine Market in North America is expected to account for the largest share globally and also grow at a faster rate during the forecast period.
Surging research activities in the field of regenerative medicine, the introduction of CAR-T cell therapies and growing awareness of personalized medicine have also resulted in the establishment of stem cell banking and tissue engineering.Read a Press Release on “Regenerative Medicine Market”:https://www.marketsandmarkets.com/PressReleases/regenerative-medicine.aspThe major players in this market are Kite Pharma (US), Novartis (Switzerland), Vericel Corporation (US), Integra LifeSciences (US), Wright Medical (US), MiMedx (US), Osiris Therapeutics (US), Stryker Corporation (US), and Spark Therapeutics (US).
The Global Hemophilia Treatment Market size is anticipated to grow at a CAGR of 6.9% during the forecast period.
Hemophilia is expected to be a complex disorder.
It’s a mostly inherited genetic disease that impairs the body's ability to form blood clots, a process needed to prevent bleeding.
The simplest thanks to treating hemophilia are to exchange the missing blood coagulation factor in order that the blood can clot properly.
Get free sample copy of this report @ https://bit.ly/3kUMxKy Key Developments in Hemophilia Treatment Market:In March 2019, Gene therapy for hemophilia is starting to come of age and promises to transform the way patients with this rare blood disease are treated.
In February 2019, the FDA has approved the Biologics License Application for Novo Nordisk’s long-acting factor VIII replacement treatment for adults and children with hemophilia A.
The major factors driving the CRISPR technology market include the rising funding from government and private organizations and the high adoption of CRISPR technology.The CRISPR Technology marketis expected to grow from USD 562 million in 2018 to USD 1,715 million by 2023, at a CAGR of 25% during the forecast period.The CRISPR services market is segmented into gRNA design and vector construction, cell line engineering, screening services, and other CRISPR services (mediated transcriptome editing and epigenome editing services).
The cell line engineering services segment is expected to grow at the highest rate.Download PDF Brochure @https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=134401204The biomedical applications segment is projected to be the fastest-growing segment of the market, by application, during the forecast period.
Developments in gene therapy, drug discovery, and diagnostics, due to the application of CRISPR, are driving the growth of this biomedical segment.
Many companies have also invested in drug discovery and gene therapy companies that are using CRISPR technology.View complete press release:-https://www.marketsandmarkets.com/PressReleases/crispr-technology.asp
